Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Scan Reader Criteria (5 total readers):~* Board-certified in radiology or nuclear medicine~* Professional experience interpreting PET scans~Scan Criteria (205 total scans):~* Former enrollment in AZES Study~* Flortaucipir scan at baseline~* clinical dementia rating - sum of boxes (CDR-SB) assessment at 18 months~Scan Study Population (AZES Study):~* 55 to 85 years~* MCI due to AD or probable AD by National Institute on Aging-Alzheimer's Association criteria (Albert 2011~* mini-mental status exam (MMSE) of 20 to 30 inclusive~* CDR global score of 0.5 (MCI), or 0.5 or 1 (AD) with a memory box score ≥ 0.5, and a score of ≤85 on the Delayed Memory Index of the Repeatable Battery for the Assessment of Neuropsychological Status.~* Amyloid positive status confirmed by florbetapir PET or lumbar puncture

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Flortaucipir PET Scan (Type: EXPERIMENTAL): No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.

Based on this trial design, predict the completion outcome and termination type (if applicable).